Literature DB >> 6100477

Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review.

L Helson.   

Abstract

A review of the pharmacological background and clinical activity of different Ca2+ channel blockers concerning reversal of anticancer drug resistance in tumors suggests that verapamil and trifluoperazine may be the most immediate candidates. Reversal of resistance to anthracyclines and vinca alkaloids originally observed in mouse experimental leukemia cell lines has now been extended to other animal cell lines and human tumors as well. Evidence is available that resistance to drugs of other classes such as dactinomycin, etoposide, and mitoxantrone can be reversed by various calcium channel blockers. Apart from enhancing retention of anticancer drugs in tumor cells, little is actually known of the mechanism(s) by which this phenomenon occurs. There is inconclusive evidence for the role of Ca2+ ions and Ca2+ channel receptors in the process, and, furthermore, there is no evidence that Ca2+ channel blocking activity per se is necessary for the reversal of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6100477     DOI: 10.1089/cdd.1984.1.353

Source DB:  PubMed          Journal:  Cancer Drug Deliv        ISSN: 0732-9482


  12 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

2.  Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Authors:  J M Onoda; K K Nelson; S M Pilarski; N S White; R G Mihu; K V Honn
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

3.  Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.

Authors:  J Timar; H Chopra; X Rong; J S Hatfield; S E Fligiel; J M Onoda; J D Taylor; K V Honn
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 4.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.

Authors:  G J Schuurhuis; H J Broxterman; J J van der Hoeven; H M Pinedo; J Lankelma
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain.

Authors:  A M Van der Bliek; M B Meyers; J L Biedler; E Hes; P Borst
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

7.  Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.

Authors:  H J Broxterman; H M Pinedo; G J Schuurhuis; J Lankelma
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

8.  An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.

Authors:  Lishuang Qi; Yang Li; Yuan Qin; Gengen Shi; Tianhao Li; Jiasheng Wang; Libin Chen; Yunyan Gu; Wenyuan Zhao; Zheng Guo
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

9.  Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.

Authors:  S Kondo; D Yin; T Morimura; H Kubo; S Nakatsu; J Takeuchi
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

10.  Nifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusion.

Authors:  O Thews; M Hummel; D K Kelleher; B Lecher; P Vaupel
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.